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Background: A randomized, controlled trial was conducted in an outpatient setting to exam-
ine the effect of beta-blocker dosing frequency on patient compliance, clinical outcome, and 
health-related quality of life in patients with stable angina pectoris. 
Methods: One hundred and twelve beta-blockers-naive outpatients with stable angina pectoris 
were randomized to receive betaxolol, 20 mg once daily or metoprolol tartrate, 50 mg twice 
daily for 8 weeks. The principal outcome measure was overall compliance measured electroni-
cally, whereas secondary outcome measures were drug effectiveness and health-related quality 
of life. 
Results: The overall compliance was 86.5 ± 21.3% in the betaxolol group versus 76.1 ± 26.3% 
in the metoprolol group (p < 0.01), and the correct number of doses was taken on 84.4 ± 21.6% 
and 64.0 ± 31.7% of treatment days, respectively (p < 0.0001). The percentage of missed doses 
was 14.5 ± 21.5% in the once-daily group and 24.8 ± 26.4% in the twice-daily group (p < 0.01). 
The percentage of doses taken in the correct time window (58.6% vs 42.0%, p = 0.01), correct 
interdose intervals (77.4% v 53.1%, p < 0.0001), and therapeutic coverage (85.6% vs 73.7%, 
p < 0.001) were signiﬁ  cantly higher in the once-daily group. Both studied drugs had similar 
antianginal effectiveness. Health-related quality of life improved in both groups, but this increase 
was more pronounced in the betaxolol arm in some dimensions. 
Conclusions: The study demonstrates that patient compliance with once-daily betaxolol is 
signiﬁ  cantly better than with twice daily metoprolol. Similarly, this treatment provides better 
quality of life. These results demonstrate possible therapeutic advantages of once-daily over 
twice-daily beta-blockers in the treatment of stable angina pectoris.
Keywords: patient compliance, quality of life, stable angina pectoris, randomized controlled 
trial, betaxolol, metoprolol, beta-blockers
Introduction
Non-compliance is a frequent phenomenon in outpatient care. It is estimated that, 
in general, at least 50% of patients fail to receive full treatment beneﬁ  t due to inad-
equate compliance (Roter et al 1998). This, in turn, leads to profound consequences. 
Non-compliance is a cause of additional procedures or treatment, and it contributes 
to unnecessary hospital admissions: up to 10% hospitalizations are attributed to this 
misbehavior (Sullivan and Kreling 1990; Malhotra et al 2001; Hope et al 2004). With 
its enormous cost burden, non-compliance is not only a serious medical problem, but 
also a social problem. 
Low compliance is a well-known phenomenon in asymptomatic diseases of which 
hypertension is the most frequently studied one. In contrast to this condition, ischemic 
heart disease is a classical example of symptomatic disease. Thus, one may assume 
that chest pain episodes should motivate patients to follow doctors’ instructions. Vascular Health and Risk Management 2007:3(2) 236
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Nevertheless, even anti-anginal treatment with symptom-
releasing drugs such as nitrates is not fully executed by 
patients (Kardas 2004). 
Beta-blockers are the drugs of choice in the therapy 
for chronic stable angina. In their case, non-compliance 
seems to be present as well, despite possible consequences. 
A recent study based on self-reports found as many as 56% 
of coronary artery disease patients non-compliant with this 
class of drugs (Newby 2006). However, unlike the other 
antianginal treatment, which with non-compliance became 
just ineffective, the consequences of non-compliance with 
beta-blockers are much more profound and include increased 
risk of incident coronary heart disease and death (Horwitz 
et al 1990; Psaty et al 1990). Thus, the problem of patient 
compliance during beta-blocker treatment is of highest 
clinical importance.
A number of factors such as intelligence, memory, age, 
education, and a number of drugs a patient takes does not 
seem to inﬂ  uence the level of adherence (Cramer 2002). On 
the contrary, existing experience points to the number of 
daily doses as an important predictor of patient compliance 
(Claxton et al 2001), although the beneﬁ  t of once-daily over 
twice-daily dosing is still not fully proved in a number of 
clinical conditions. Two decades ago, this concept was tested 
in the ﬁ  eld of beta-blockers, revealing better compliance 
with once-daily formulation (Baird et al 1984). However, 
the methodology of that study, ie, the assessment of compli-
ance by means of simple pill count, did not allow any insight 
in dose timing history and until now little is known about 
patient compliance with beta-blockers. Recently, new pos-
sibilities have come with the use of electronic monitoring, 
which is the most precise method of compliance assessment. 
This methodology has been shown to be more accurate in 
revealing non-compliance than reﬁ  ll data, pill count, provider 
assessment, or patient self-reporting (Vrijens and Urquhart 
2005). Therefore, the BETTER trial (once-daily betaxolol 
vs twice-daily metoprolol: the effect on patient compliance 
and clinical outcome) aimed to precisely assess the impact of 
different dosing regimens of beta-blockers on compliance and 
clinical outcome to ﬁ  nd out whether once-daily beta-blocker 
regimen ensures real clinical advantage.
Materials and methods
Patients and study design
This was an open, randomized, single-center, parallel-
group study, investigating compliance in patients treated 
with betaxolol or metoprolol. The study protocol has been 
a priori approved by the Ethical Committee of the Medical 
University of Lodz. 
The inclusion criteria were ischemic heart disease outpa-
tients CCS class I-II, aged 40–75 years, beta-blockers-naive, 
whose mental state enabled conscious participation in the 
study and who had signed a conscious consent form.
The main exclusion criteria were unstable angina pectoris, 
NYHA class III and IV heart failure, heart rate <60/min, II˚ or 
III˚ atrio-ventricular block, systolic blood pressure below 90 
mmHg, symptomatic infection, and any conditions requiring 
help of others with drug administration (eg, impaired dexter-
ity, serious visual defect).
The sample size of 48 patients in each group was obtained 
by assuming overall compliance (primary outcome measure) 
difference between the group of 10%, and common stan-
dard deviation of 15%, with a power of 90% and α = 0.05 
(Rosner 2000). Therefore, the study was designed to cover 
100 patients.
At the ﬁ  rst visit, the eligibility criteria were assessed and 
written informed consent was obtained. All patients were 
provided with self-control diaries, in which they were asked 
to record the number of chest pain episodes per week and the 
number of short-acting nitrate doses taken in case of need 
(eg, nitroglycerine in tablets or aerosol, izosorbide dinitrate 
in aerosol) as well as any relevant information concerning 
health and medication.
After the next 2 weeks of observation, patients were 
randomized to the two groups: the once-daily (od) 
group was informed to take 20 mg betaxolol (Lokren®, 
Sanoﬁ  -Synthelabo, France) at 07:00; and the twice-daily 
(bd) group was informed to take 100 mg metoprolol tartrate 
(metoprolol, ICN Polfa Rzeszow, Poland) in two 50 mg 
doses, to be taken at 07:00 and 19:00.
The active treatment phase was designed for 8 weeks, 
and the patients received the amount of drug sufﬁ  cient for 
10 weeks therapy, in MEMS® vials. 
Measurement of compliance by MEMS 
Patient compliance was measured by an electronic monitor-
ing system (MEMS, Medication Event Monitoring System, 
Aardex, Zug, Switzerland). The MEMS container consists 
of a standard tablet bottle and a cap containing a micropro-
cessor that registers the date and time of every opening. The 
patients were fully familiarized with the aim and method of 
study and instructed how to use MEMS container correctly, 
that is, to open it for no other reason but to take out tablets 
directly before use.Vascular Health and Risk Management 2007:3(2) 237
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For the purpose of calculations, multiple MEMS openings 
within a short period of time (≤15 min) were ﬁ  ltered and not 
counted. All other recorded openings were considered to 
represent a single dose intake. 
The following parameters were employed for patient 
compliance assessment:
•  Overall compliance, which was deﬁ  ned by the number of 
container openings divided by the number of prescribed 
doses for the treatment period, and expressed as a percent-
age. Overall compliance was chosen to be the primary 
outcome measure. 
•  Days with correct number of doses taken were deﬁ  ned as 
a percentage of the treatment days with one or two doses 
taken for od and bd regimens, respectively. 
•  Doses taken in correct time window were deﬁ  ned as a 
percentage of the doses taken between 05:00 and 09:00 
for once-daily dosage and between 06:00 and 08:00 and 
18:00 and 20:00 for twice-daily dosage.
•  Correct interdose intervals were deﬁ  ned as the number of 
correct interdose intervals divided by the number of inter-
dose intervals between prescribed doses, and expressed 
as a percentage. Interdose interval was judged correct 
when the dose was taken within the period of 20–28 h 
after the previous dose intake in case of od regimen and 
within the period of 10–14 h after the previous dose in 
case of bd regimen.
•  Missing doses were calculated according to the absence 
of registered dose intake during the periods “midnight 
to midnight” (24 h) in case of od regimen and “midnight 
to midday” or “midday to midnight” (two 12 h periods) 
in case of bd regimen, respectively, and expressed as 
percentage of prescribed doses.
•  Therapeutic coverage was expressed as a percentage of 
the studied period covered with drug activity, arbitrary 
assuming a drug action up to 24 h after single-dose intake 
for od regimen and up to 12 h for bd regimen.
Drug effectiveness and tolerance; 
health-related quality of life 
Drug effectiveness was assessed with the weekly number 
of chest pain episodes and weekly number of short-acting 
nitrates doses, both established on the basis of patients’ 
self-report diaries. The effect of treatment on quality of life 
was assessed with the means of especially designed 6-item 
questionnaire. Moreover, general health-related quality of life 
was assessed with the means of EuroQol-5D (EQ-5D) generic 
questionnaire, which covers 5 dimensions: mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression 
(Rabin and de Charro 2001).
Data processing and statistical analysis
Data from MEMS containers were transferred into a com-
puter and processed using the PowerViev v. 1.3.2 program 
(Aardex, Zug, Switzerland). Qualitative variables were com-
pared using a chi2 test. Quantitative data were expressed as 
means ± SD (standard deviation) and were compared using 
Mann-Whitney test. The statistical signiﬁ  cance threshold 
was chosen at p < 0.05.
Results
Baseline characteristics 
One hundred and twelve patients entered the study and were 
randomized: 56 patients to each od and bd group. Thirteen 
patients were excluded from the analysis for different reasons 
(1 patient due to premature withdrawal, 6 due to premature 
termination due to adverse effects, and 6 patients for protocol 
violation). The compliance analysis was ﬁ  nally performed for 
96 patients (47 in betaxolol and 49 in metoprolol group) due 
to a MEMS container lost in 2 cases and failure to download 
compliance data from the MEMS cap in 1 case. 
The patients’ demographic characteristics are given in 
Table 1. The two groups did not differ in terms of age, sex, 
and the average number of monitored days.
Overall compliance
Overall compliance assessed electronically by MEMS was bet-
ter with once-daily than with twice-daily treatment: patients on 
betaxolol took 86.5% of recommended doses on average, while 
patients on metoprolol took 76.1% (p < 0.005) (Table 2). 
Assessment of daily compliance by MEMS
The difference in the percentage of days with the correct num-
ber of doses taken between the groups was highly signiﬁ  cant 
in favor of the betaxolol group (84.4% vs 64.0%, p < 0.0001). 
There was no signiﬁ  cant difference in days with no dose and 
days with extra doses, although these two values were slightly 
lower in the od group. 
The number of missed doses in the metoprolol group was 
nearly twice that of the betaxolol group (24.8% vs 14.5%, 
p < 0.05).
Timing compliance
In the betaxolol group, 58.6% of prescribed doses were taken 
in the correct time window compared with only 42.0% in Vascular Health and Risk Management 2007:3(2) 238
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the metoprolol group (p = 0.01) (Table 2). A statistically 
signiﬁ  cant difference was also observed between the groups 
concerning correct interdose intervals: 77.4% of doses in 
the od group were taken with correct interdose intervals 
versus only 53.1% in the bd group (p < 0.0001). Similarly, 
therapeutic coverage was signiﬁ  cantly better in the betaxolol 
group (85.6% vs 73.7%, p = 0.0005).
Treatment effectiveness
Treatment effectiveness assessment revealed similar decrease 
in the number of chest pain episodes per week compared with 
baseline (ie, averaged number for initial 2-weeks drug-free 
period) in both od and bd groups (0.42/week and 0.46/week, 
respectively, p > 0.05) as well as reduction in the weekly 
number of short-acting nitrate doses taken in case of need 
(0.30/week and 0.21/week, respectively, p > 0.05) (Figure 1).
Health-related quality of life
The health-related quality of life parameters results 
are listed in Table 3 and 4. None of the general health-
related quality of life parameters assessed by EQ-5D (ie, all 5 
dimensions scores as well as mean EQ-5D utility score and 
EQ-5D visual analog scale [VAS] results) differed between 
od and bd groups neither at randomization nor ﬁ  nal visit. 
However, a positive change was observed in both groups in 
case of usual activities, pain/discomfort (especially in the od 
group), and anxiety/depression dimensions of EQ-5D, and 
in the betaxolol group in case of mobility, which altogether 
resulted in positive change to mean EQ-5D utility scores in 
both od and bd groups. Similarly, EQ-5D VAS scores have 
improved during the follow-up. These results were consis-
tent with those of the speciﬁ  c questionnaire, which showed 
a marked improvement in general well-being (over 70% of 
patients in both groups), and an important increase in physical 
function in the od group only. 
When ﬁ  lling the speciﬁ  c questionnaire at ﬁ  nal visit, 
patients expressed a marked improvement in their general 
well-being (72% of patients) and modest one in terms of 
sleep (33% of patients), and mood (40% of patients). There 
was marked improvement in physical function in betaxolol 
group (43%) versus only slight in metoprolol group (15%). 
Both treatments had no inﬂ  uence on physical function and, 
notably, on sexual function (Table 4).
Tolerance and adverse effects
Adverse effects occurred in 13.4% of patients (in 10.7% within od 
and 16.1% within bd groups). The most common adverse effect 
was bradycardia (3.5% in both groups). Adverse effects were 
the reason for patient withdrawal in 6 cases: 2 in the betaxolol 
group, and 4 in the metoprolol group. In most cases, adverse 
effects were transient and slightly expressed, no severe adverse 
event was observed in the trial.
Table 1 Demographic characteristics of studied groups 
  Together (n = 96)  od Betaxolol (n = 47)  bd Metoprolol (n = 49)  P
Age (mean ± SD)  56.8 ± 9.9  58.5 ± 9.9  55.0 ± 9.6  ns
Male (%)  40.6  34.0  46.9  ns
Number of monitored days   66.0 ± 16.4  65.6 ± 11.8  66.3 ± 19.9  ns
(mean ± SD)
ns = p > 0.05
Table 2 Parameters of patient compliance in studied groups (parameters are expressed as mean ± SD) 
Parameter od  Betaxolol  bd  Metoprolol  p
  (n = 47)  (n = 49)
Overall compliance (%)  86.5 ± 21.3  76.1 ± 26.3  0.002
Days with correct number      
of doses taken (%)  84.4 ± 21.6  64.0 ± 31.7  <0.0001
Days with no dose (%)  14.5 ± 21.4  15.2 ± 24.2  ns
Days with extra doses (%)  1.0 ± 1.2  1.6 ± 2.6  ns
Missing doses (%)  14.5 ± 21.5  24.8 ± 26.4  0.004
Doses taken in correct      
time window (%)  58.6 ± 31.9  42.0 ± 28.0  0.01
Correct interdose intervals (%)   77.4 ± 26.6  53.1 ± 32.5  <0.0001
Therapeutic coverage (%)   85.6 ± 21.2  73.7 ± 25.8  0.0005
Pill count (%)  94.8 ± 16.2  88.8 ± 24.7  ns
ns = p > 0.05Vascular Health and Risk Management 2007:3(2) 239
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Discussion
Although the negative relation between non-compliance 
and clinical outcome seems to be obvious, the power of 
this relation differs greatly among the treatments (Hughes 
et al 2001). Indeed, even in the cardiovascular area, some 
drugs are more forgiving, and the condition for which 
they are prescribed is less life-threatening. In the case of 
lipid-lowering drugs, for example, there is no direct danger 
connected with skipping a dose, or even drug holidays (ie, 
discontinuation of treatment for 3 days or longer). On the 
other hand, there are drugs for which doctor’s advice needs to 
be followed very carefully. Relatively small non-compliance 
with warfarin may result in life-threatening hemorrhagic or 
thrombotic complications.
Among the antianginal drugs, beta-blockers are par-
ticularly sensitive to non-compliance. Rapid cessation of 
their use is connected with increased risk of exacerbation 
of angina and acute coronary event, including heart attack, 
and death. Subjects who stop using beta-blocker medica-
tion have a transient four-fold increase in the relative risk 
of cardiovascular event (Psaty et al 1990). Those who do 
not adhere well to treatment regimen (ie, who took no more 
than 75% of prescribed medication) are 2.6 times more 
likely than good adherers to die within a year of follow-up 
(Horwitz et al 1990).
Results of the present study prove that once-daily dosing 
of beta-blockers in stable angina pectoris leads to signiﬁ  -
cantly better compliance than twice-daily as conﬁ  rmed by 
overall compliance, days with the correct number of doses 
taken, and missing doses. Similar results were obtained for 
beta-blockers in hypertension, where those taking at least 
Figure 1  The changes in weekly number of chest pain episodes and additional 
short-acting nitrates taken in case of need with time in studied groups. Two initial 
weeks constitute baseline period.
Table 3 EQ-5D dimension scores and visual analog health  scale (VAS) scores at randomization (V0) and the ﬁ  nal visit (V8) 
Dimension V0    V8
  Betaxolol Metoprolol  Betaxolol Metoprolol
  (n = 47)  (n = 49)  (n = 47)  (n = 49)
Mobility      
No difﬁ   culties  (%)  73.9 69.4  86.4 71.4
Some difﬁ   culties  (%)  26.1 28.6  13.6 26.5
Extreme difﬁ   culties  (%)  0 2.0  0 2.0
Self-care      
No difﬁ   culties  (%)  91.3 93.9  95.5 89.8
Some difﬁ   culties  (%)  8.7 6.1  4.5 10.2
Extreme difﬁ   culties  (%)  0 0  0 0
Usual activities      
No difﬁ   culties  (%)  76.1 71.4  81.8 81.6
Some difﬁ   culties  (%)  23.9 28.6  18.2 18.4
Extreme difﬁ   culties  (%)  0 0  0 0
Pain/discomfort      
No difﬁ  culties (%)  26.1d 18.4d 72.7d 57.1d
Some difﬁ  culties (%)  73.9d 81.6d 27.3d 42.9d
Extreme difﬁ   culties  (%)  0 0  0 0
Anxiety/depression      
No difﬁ  culties (%)  41.3b 38.8c 63.4b 69.4c
Some difﬁ  culties (%)  58.7b 61.2c 36.4b 30.6c
Extreme difﬁ   culties  (%)  0 0  0 0
Mean EQ-5D utility  1.38 ± 0.49a  1.42 ± 0.50b 1.20  ±  0.40a  1.27 ± 0.45b
Mean EQ-5D VAS   63.3 ± 14.0d  63.1 ± 15.6d  75.8 ± 13.0d 75.0  ±  10.9d
ap = 0.05 between V0 and V8, bp < 0.05 between V0 and V8, cp < 0.01 between V0 and V8, dp < 0.001 between V0 and V8.
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90% of prescribed doses constituted 92.8% of the od group 
and 81.5% in the bd group (p = 0.009) (Baird et al 1984). 
Other studies found comparable trends for other antianginal 
treatments (Brun 1994; Detry et al 1994; Kardas 2004). 
However, in some studies comparing once- and twice-
daily dosing, better compliance for once-daily regimen was 
accompanied by higher percentage of no-dosing days. In 
a cross-over study comparing amlodipine once-daily and 
nifedypine SR twice-daily in the treatment of hypertension 
and angina pectoris, taking compliance improved in 30% of 
patients when switching from twice-daily to once-daily regi-
men but, at the same time, there was a 15% increase in the 
number of patients with one or more no-dosing days (Erne 
et al 1994). For this reason, twice-daily regimen was re-
garded as superior to once-daily regimen by some authors 
(Haynes et al 2002). Moreover, in some studies the number 
of days with extra doses was higher for once-daily drugs 
than for twice-daily ones, which could lead to overdosing 
(Winkler et al 2002). Contrary to these ﬁ  ndings, in the 
present study, no difference with respect to days with no 
doses and days with extra doses between once-daily and 
twice-daily groups was found. 
A satisfactory timing compliance does not always fol-
low a good dosing one. In extreme cases, only 17%–33% 
of drug doses were taken within an acceptable time interval 
(ie, 12 ± 3 h after previous dose in case of twice-daily dos-
ing), although overall compliance was nearly perfect at 
97%–99.6% (Rudd et al 1992; Favre et al 1997). However, 
betaxolol, used in the present study as an od drug due to its 
long elimination half-life, was proven to maintain the effect 
on both blood pressure and heart rate longer than some other 
beta-blockers, even when some doses are missed (Johnson 
and Whelton 1994). Moreover, the present study revealed 
better timing compliance (in terms of doses taken in correct 
time window, correct interdose intervals, and therapeutic 
coverage) with this drug, than with its bd comparator.
Results of studies performed in this ﬁ  eld point at the strict 
association between compliance and treatment effectiveness 
(Hughes et al 2001). This rule was proved in a number of 
cardiovascular conditions and treatments (Cramer 2002). 
Among over 4000 diabetic patients in a longitudinal study, 
od regimen was correlated with signiﬁ  cantly better compli-
ance and glycemic control after 6 months’ follow-up, with 
a signiﬁ  cant decrease of HbA1c level (Guillausseau 2004). 
Some recent studies, which employed electronic monitoring 
to assess compliance, clearly proved that once-daily regimen 
leads not only to better compliance, but also to better effec-
tiveness (Kardas 2004, 2005).
Nevertheless, good adherence to beta-blockers is a nec-
essary precondition for patients to beneﬁ  t from this type of 
treatment (Wei et al 1994). It was observed that omission of 
short-acting beta-blocker resulted in signiﬁ  cantly increased 
blood pressure and heart rate during the following two days 
(Johnson and Whelton 1994). Betaxolol, the once-daily 
administered beta-blocker used in the present study, proved 
to be effective in the treatment of stable angina pectoris, 
reducing angina pectoris frequency and improving exercise 
capacity (Alpert et al 1990; Narahara 1990; Chrysant and 
Bittar 1994). Due to its long plasma t1/2 betaxolol was found 
to provide a long-lasting reduction in exercise-induced isch-
emia, longer than that found with atenolol (McLenachan et al 
1992). Similarly, in this study patients on betaxolol revealed 
more pronounced improvement in their “pain/discomfort” 
dimension of quality of life assessment as well as physical 
function, compared with the metoprolol group.
Beta-blockers were found to be effective in increasing 
quality of life in case of heart failure as well as hypertension 
(Fowler 1998; Haneda et al 1998; Reddy and Dunn 2000). 
Due to their antianginal effect, they also enhance quality of 
life in case of ischemic heart disease. Betaxolol has been 
Table 4 Changes to the quality of life dimensions after 8 weeks 
of active treatment
Dimension   Final  visit 
  Betaxolol     Metoprolol    
  (n = 42)a(%)    (n = 46)(%)
General well-being  
Improved (%)  73.2  71.7
No change (%)  24.4  28.3
Deteriorated (%)  2.4  0.0
Sleep  
Improved   31.0  34.8
No change   66.7  65.2
Deteriorated   2.4  0.0
Mood  
Improved   42.9  37.0
No change   52.4  60.9
Deteriorated   4.8  2.2
Psychical function  
Improved   19.0  13.0
No change   78.6  87.0
Deteriorated   2.4  0.0
Physical function  
Improved   42.9b 15.2b
No change   57.1b 84.8b
Deteriorated   0.0  0.0
Sexual function  
Improved   0.0  4.3
No change   100.0  95.7
Deteriorated 0.0  0.0
afor General well-being n = 41, bp < 0.01 between two groups.Vascular Health and Risk Management 2007:3(2) 241
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recently found to enhance quality of life in patients with heart 
failure (Figulla et al 2005). In a placebo-controlled study in 
hypertension, the effect of betaxolol treatment on well-being, 
physical state, sexual functioning, and sleep was similar to 
placebo, whereas cognitive acuity was slightly attenuated in 
this treatment group (Ameling et al 1991). Contrary to that 
ﬁ  nding, in the present study both betaxolol and metoprolol 
had a beneﬁ  cial inﬂ  uence on general well-being, which was 
particularly marked in pain, discomfort, and mood dimen-
sions (Tables 3 and 4). Noteworthy, this beneﬁ  cial effect, at 
least in some aspects of quality-of-life assessment, seems to 
be more pronounced for od betaxolol than bd metoprolol, 
and one may speculate to what extent it is associated with 
simpler regimen, better compliance, and greater effectiveness 
connected with this treatment.
In assessing results of this study, it is necessary to re-
member its limitations. At ﬁ  rst, due to ethical reasons, all 
patients were informed about the aim of the study, which 
could positively affect compliance. However, it is believed 
that this effect decreases with the time of treatment, and 
an 8-week active treatment study period is long enough to 
minimize it. Another source of limitation is using self-re-
porting diaries for recording symptoms, not the objective 
method, which could result in potential underestimation 
of anginal episodes. Indeed, limited usefulness of diaries 
has been proved recently by comparison with electronic 
measurement (Stone et al 2002). Nevertheless, neither the 
difference in compliance nor in effectiveness between the 
groups may be attributed to these factors, as both study 
arms were given the same conditions. Finally, beta-blockers 
used in this study not only differ in their pharmacokinetic 
properties (betaxolol, t1/2 14–20 h, metoprolol, t1/2 3–4 h), 
but they also have different pharmacodynamic properties. 
Therefore, in their typical dosage, 20 mg of betaxolol 
might induce slightly more beta-blockade than 100 mg of 
metoprolol tartrate (Borchard 1998).
Conclusions
The study compared compliance in patients with stable 
angina pectoris, taking od versus bd beta-blockers. Using 
electronic measurement (MEMS), it has been found that 
patient compliance with od betaxolol is signiﬁ  cantly higher 
than with bd metoprolol tartrate in terms of both dosing and 
timing. Moreover, patients on od betaxolol achieved better 
quality of life. Therefore, once-daily betaxolol seems to be 
an especially attractive beta-blocker which combines good 
compliance with low sensitiveness for missed doses and 
ensures not only high efﬁ  cacy in clinical trials, but also high 
effectiveness in real life conditions. The results point also 
at general therapeutic advantage of once-daily administered 
beta-blockers over twice-daily administered ones in the 
treatment of stable angina pectoris, which is of high clinical 
relevance due to the life-threatening consequences of non-
compliance in case of this treatment.
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